Treating ALL patients with T cells targeted for CD19

Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies

T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence

Removal of alpha/beta T cells and of CD19 B cells in children With acute leukaemia

Transplantation and short telomeres increase the risk of cognitive impairment

Final stage II results of the CLL11 trial

Results from the randomised phase III Children’s Oncology Group (COG) trial, AAML0531

Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease

Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy

Equality of access to transplant for ethnic minority patients

Effective treatment of chemotherapy-refractory diffuse large B cell lymphoma

Encouraging outcomes in older patients following nonmyeloablative haploidentical blood or marrow transplantation